ArticleInternational journal of clinical oncology2013
Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer.
Article in International journal of clinical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A Systematic Review and Meta-analysis on the Occurrence of Biomarker Mutation in Colorectal Cancer among the Asian Population.BioMed research international · 2022Pooled it
- Pooled it
- Integrated NGS and ddPCR analysis of RAS/RAF mutations in metastatic colorectal cancer among Kazakhstani patients: a pilot study.Frontiers in medicine · 2026Article
- Severe symptomatic cardiac dysfunction in a patient with BRAF V600E-mutated metastatic colorectal cancer treated with encorafenib, binimetinib, and cetuximab: a case report.Journal of pharmaceutical health care and sciences · 2025Article
- A Study of Molecular Subtypes (Profile) of Colorectal Cancer and Their Correlation with Clinical and Pathological Profile in a Tertiary Care Center in India.South Asian journal of cancer · 2025Article
- Multigene Panel Next-Generation Sequencing Techniques in the Management of Patients with Metastatic Colorectal Carcinoma: The Way Forward for Personalized Treatment? A Single-Center Experience.International journal of molecular sciences · 2024Article
- Exploring the Relationship Between KRAS, NRAS, and BRAF Mutations and Clinical Characteristics in Iranian Colorectal Cancer Patients.Journal of gastrointestinal cancer · 2024Article
- Review
- Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability.Journal of gastrointestinal cancer · 2020Article
- KRAS and BRAF mutations in Iranian colorectal cancer patients: A systematic review and meta-analysis.Caspian journal of internal medicine · 2020Review
- Unique characteristics of CpG island methylator phenotype (CIMP) in a Chinese population with colorectal cancer.BMC gastroenterology · 2019Article
- Clinicopathological Significance ofJournal of Cancer · 2019Article
- Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study.Neoplasia (New York, N.Y.) · 2018Article
- Clinical significance of the BRAFV600E mutation in Asian patients with colorectal cancer.International journal of colorectal disease · 2018Article
- Development of ultra-short PCR assay to reveal BRAF V600 mutation status in Thai colorectal cancer tissues.PloS one · 2018Article
- The pattern of KRAS mutations in metastatic colorectal cancer: a retrospective audit from Sri Lanka.BMC research notes · 2017Article
- Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer.Journal of cancer research and clinical oncology · 2017Article
- Association between clinicopathological features and survival in patients with primary and paired metastatic colorectal cancer andOncoTargets and therapy · 2017Article
- Molecular spectrum ofJournal of gastrointestinal oncology · 2016Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMutations of the KRAS or BRAF genes are now recognized as prognostic markers for colorectal cancer (CRC). They are also important predictive markers for resistance to the monoclonal antibodies that target the epidermal growth factor receptor.
methodsIn this retrospective study, KRAS and BRAF mutations were analyzed using a direct sequence method in 254 Japanese CRC patients, and the associations between KRAS or BRAF mutations and clinicopathological characteristics or outcome were evaluated.
resultsKRAS and BRAF mutations were detected in 33.5 and 6.7 % of all patients, respectively. Consistent with previous reports, BRAF mutations were significantly correlated with the anatomical site of the tumor (P < 0.001), tumor grade (P = 0.001) and high frequency of microsatellite instability (P < 0.001). BRAF mutations were correlated with poor overall survival in the full patient cohort (P = 0.009). KRAS mutations were significantly correlated with poor recurrence-free survival (P = 0.03), particularly in patients with stage II CRC (P = 0.007). Cox regression analysis showed that KRAS mutations were a negative predictor of recurrence-free survival in patients with stage II CRC.
conclusionKRAS mutation status could be a novel biomarker for predicting disease recurrence in Japanese patients with stage II CRC.
Indexed as
Identifiers
23188063What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.